INmune Bio Stock (NASDAQ:INMB)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.04

52W Range

$4.78 - $14.74

50D Avg

$5.64

200D Avg

$8.99

Market Cap

$138.58M

Avg Vol (3M)

$250.07K

Beta

1.85

Div Yield

-

INMB Company Profile


INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Feb 04, 2019

Website

INMB Performance


INMB Financial Summary


Dec 23Dec 22Dec 21
Revenue$-155.00K$374.00K$181.00K
Operating Income$30.01M$-25.95M$-29.15M
Net Income$30.01M$-28.65M$-30.34M
EBITDA$30.01M$-25.95M$-29.15M
Basic EPS-$-1.60$-1.88
Diluted EPS-$-1.60$-1.88

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 31, 24 | 8:09 PM
Q2 24Aug 01, 24 | 11:50 PM
Q1 24May 09, 24 | 12:00 AM

Peer Comparison


TickerCompany
CUECue Biopharma, Inc.
AVXLAnavex Life Sciences Corp.
DBTXDecibel Therapeutics, Inc.
TCRXTScan Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
DRMADermata Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
BIVIBioVie Inc.
INABIN8bio, Inc.
TFFPTFF Pharmaceuticals, Inc.
SAVACassava Sciences, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
CGTXCognition Therapeutics, Inc.
ANIXAnixa Biosciences, Inc.
PYPDPolyPid Ltd.
ELYMEliem Therapeutics, Inc.